PLX PAD

Drug Profile

PLX PAD

Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; Allogeneic mesenchymal-like adherent stromal cells; PLacental eXpanded cells; PLX-PAD cell therapy

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pluristem Therapeutics
  • Class Ischaemic heart disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia; Thromboangiitis obliterans
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Peripheral arterial disorders
  • Phase II Intermittent claudication; Muscle injury
  • Phase I Pulmonary arterial hypertension
  • Preclinical Duchenne muscular dystrophy; Ischaemic heart disorders; Preeclampsia; Tendon injuries

Most Recent Events

  • 18 Sep 2017 PLX PAD receives Fast Track designation for Peripheral arterial disorders [IM,Injection] (In the elderly, In adults) in USA
  • 13 Sep 2017 Pluristem Therapeutics has patent protection for placental expanded (PLX) cells for the treatment of Critical limb ischaemia and muscle regeneration in Hong Kong
  • 11 Sep 2017 Phase-III clinical trials in Peripheral arterial disorders (In adults, In the elderly) in Austria (IM), before September 2017 (NCT03006770)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top